Jazz Pharmaceuticals plc
JAZZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4,068,950 | $3,834,204 | $3,659,374 | $3,094,238 |
| % Growth | 6.1% | 4.8% | 18.3% | – |
| Cost of Goods Sold | $445,713 | $435,577 | $540,517 | $440,760 |
| Gross Profit | $3,623,237 | $3,398,627 | $3,118,857 | $2,653,478 |
| % Margin | 89% | 88.6% | 85.2% | 85.8% |
| R&D Expenses | $884,000 | $849,658 | $590,453 | $505,748 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,385,294 | $1,343,105 | $1,416,967 | $1,451,683 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $637,313 | $627,284 | $1,176,965 | $525,769 |
| Operating Expenses | $2,906,607 | $2,820,047 | $3,184,385 | $2,483,200 |
| Operating Income | $716,630 | $578,580 | -$65,528 | $170,278 |
| % Margin | 17.6% | 15.1% | -1.8% | 5.5% |
| Other Income/Exp. Net | -$247,939 | -$283,660 | -$317,177 | -$283,830 |
| Pre-Tax Income | $468,691 | $294,920 | -$382,705 | -$113,552 |
| Tax Expense | -$91,429 | -$119,912 | -$158,645 | $216,116 |
| Net Income | $560,120 | $414,832 | -$224,060 | -$328,954 |
| % Margin | 13.8% | 10.8% | -6.1% | -10.6% |
| EPS | 9.06 | 6.55 | -3.58 | -5.51 |
| % Growth | 38.3% | 283% | 35% | – |
| EPS Diluted | 8.65 | 6.1 | -3.58 | -5.51 |
| Weighted Avg Shares Out | 61,838 | 63,291 | 62,539 | 59,694 |
| Weighted Avg Shares Out Dil | 66,007 | 72,066 | 62,539 | 59,694 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $238,097 | $289,438 | $288,242 | $278,766 |
| Depreciation & Amortization | $660,067 | $638,696 | $629,471 | $552,483 |
| EBITDA | $1,521,711 | $1,449,422 | $1,468,615 | $1,027,746 |
| % Margin | 37.4% | 37.8% | 40.1% | 33.2% |